Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002968 · ClinicalTrials.gov registry record · Phase 3

Edrecolomab in Treating Patients With Stage II Colon Cancer

A Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
2,100
Enrollment target
1
Study location

NCT00002968 is a Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,100 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002968, a Phase 3 study of Mucinous Adenocarcinoma of the Colon and Signet Ring Adenocarcinoma of the Colon, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
2,100 participants
Enrollment target
1
Study location

Study Summary

Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether surgery to remove colon cancer is more effect with or without monoclonal antibody therapy.

Interventions

  • OTHER laboratory biomarker analysis
  • BIOLOGICAL edrecolomab

Study Locations (1)

Illinois

  • Cancer and Leukemia Group B - Chicago

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 1997-05
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00002968

The ClinicalTrials.gov registry entry for NCT00002968 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Mucinous Adenocarcinoma of the Colon appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.

NCT00002968 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00002968 about?

NCT00002968 is a clinical study titled "Edrecolomab in Treating Patients With Stage II Colon Cancer". Randomized phase III trial to compare the effectiveness of surgery with or without monoclonal antibody therapy in treating patients who have stage II colon cancer. Monoclonal antibodies such as edrecolomab can locate tumor cells and either kill them or deliver tumor-killing substances to them withou...

What is the current status of trial NCT00002968?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,100 participants. The study started on 1997-05.

What conditions does trial NCT00002968 study?

This clinical trial studies the following conditions: Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer.

What interventions are being tested in trial NCT00002968?

The interventions under investigation include: laboratory biomarker analysis (OTHER), edrecolomab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002968?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002968 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mucinous Adenocarcinoma of the Colon

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.